Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas.

A ArnoldS DaumM von WinterfeldE BergM HummelB RauU SteinChristoph Treese

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2020)

In Caucasian AEG/S patients, 17.1% appeared to be eligible for an anti-Claudin 18.2 therapy. Claudin 18.2 expression itself has no impact on prognosis and is not related to any tumor subtype.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
poor prognosis
prognostic factors
peritoneal dialysis
stem cells
patient reported outcomes
african american
bone marrow
long non coding rna
cell therapy
patient reported